JPRN-UMIN000021239
Completed
未知
Influence of SGLT2-inhibitor (Canagliflozin) in patients with DM who underwent cardiac surgery - Influence of SGLT2-inhibitor (Canagliflozin) in patients with DM who underwent cardiac surgery
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- patients with diabetes mellitus underwent cardiac surgery
- Sponsor
- Sekino Hospital
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who were deemed not appropriate to participate in this study by doctor
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Effect of SGLT2 inhibitor, canagliflozin, for the size of lipid particlesType 2 diabetesJPRN-UMIN000020027Tokyo Medical and Dental University Department of Medical Genetics / Gerontorgy30
Not yet recruiting
Phase 4
The role of SGLT-2 inhibitors (Empagliflozin) in treating steroid induced hyperglycaemia in the management of glucocorticoid induced hypoerglycaemia in adults with and without diabetes.ACTRN12620000745943Endocrinology Department, Gosford Hospital30
Completed
Phase 2
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesDiabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424NL-OMON48616Radboud Universitair Medisch Centrum15
Active, not recruiting
Phase 1
To investigate whether treatment with the SGLT-2 inhibitor dapagliflozin improves the perception of hypoglycemia in people with type 1 diabetes with impaired awareness of hypoglycemiaType 1 diabetesTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2018-001569-17-NLRadboud university medical center15
Completed
Not Applicable
Effects of treatment with SGLT2 inhibitor on the initiation of continuous positive airway pressure therapy in type 2 diabetic patients with obstructive sleep apnea syndromeType 2 diabetesJPRN-UMIN000045226Akishima Clinic16